Clinical observation of MPA and HMG used for controlled ovarian stimulation in patients with diminshed ovarian reserve

Clinical observation of MPA and HMG used for controlled ovarian stimulation in patients with diminsh

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OCH-14004176

Enrollment

Unknown

Registered

2014-01-07

Start date

2014-01-08

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility

Interventions

MPA group:MPA and HMG

control:natural cycle

Eligibility

Sex/Gender

Female

Age

25 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1) aged 25–45 years; 2) have a spontaneous menstrual cycle (21–35 days in duration); 3) antral follicle counts (AFC) < 5 on menstrual cycle day 3 or a basal serum FSH concentration between10–30mIU/ml; 4) no functional cysts present on the bilateral ovaries on menstrual cycle day 3.

Exclusion criteria

Exclusion criteria: 1) clinically significant systemic disease such as renal failure; 2) documented ovarian failure; 3) any contraindications to ovarian stimulation treatment.

Design outcomes

Primary

Measure	Time frame
incidence of LH surge; incidence of advanced ovulation;	—

Secondary

Measure	Time frame
the number of mature oocyte;the number of fertilized oocytes;the number of cleavaged embryo;	—

Countries

China

Contacts

Public ContactKuang Yanping

Shanghai Nineth People's Hospital

kuangyanp@126.com+86 021-53178080

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 9, 2026